Table 1.
Baseline characteristics of CTEPH patients and healthy controls
| CTEPH patients | Healthy controls | p | |
|---|---|---|---|
| Subjects (n) | 38 | 28 | |
| Age (years) | 63 ± 11 | 59 ± 6 | 0.13 |
| Female (n, %) | 29 (76%) | 18 (64%) | 0.286 |
| BPA sessions/patient | 2 (2–3) | ||
| Total BPA sessions | 100 | ||
| Interval between BPA (days) | 70 (34–117) | ||
| Exercise capacity | |||
| WHO functional class (Ⅰ–Ⅱ/Ⅲ–Ⅳ, %) | 50%/50% | ||
| 6MWD (m) | 369 ± 81 | ||
| Pulmonary hemodynamics | |||
| Mean RAP (mmHg) | 6 (4–10) | ||
| Systolic PAP (mmHg) | 80 ± 27 | ||
| Diastolic PAP (mmHg) | 25 ± 10 | ||
| Mean PAP (mmHg) | 44 ± 14 | ||
| PVR (Wood Unit) | 9.8 (7.2–17.1) | ||
| Cardiac output (L/min) | 3.3 (2.5–4.5) | ||
| Cardiac index (L/min*m2) | 2.0 (1.6–3.0) | ||
| PASO2 (%) | 61 ± 9 | ||
| MVSO2 (%) | 94 (91–97) | ||
| NT‐proBNP (pg/ml) | 838 (217–2114) | ||
| PAH‐targeted therapy (n, %) | 23 (60.5%) | ||
| Riociguat | 13 (34.2) | ||
| Macitentan | 2 (5.3) | ||
| Treprostinil | 7 (18.4) | ||
| Tadalafil | 3 (7.9) | ||
| Sildenafil | 3 (7.9) | ||
| Ambrisentan | 2 (5.3) | ||
| Anticoagulation (n, %) | 38 (100%) | ||
| Warfarin | 8 (21.1) | ||
| Rivaroxaban | 28 (73.7) | ||
| Dabigatran | 2 (5.3) |
Note: Data are presented as median and interquartile range or n (%).
Abbreviations: 6MWD, 6 min walk distance; CTEPH, chronic thromboembolic pulmonary hypertension; MVSO2, mixed venous oxygen saturation; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; PASO2, pulmonary arterial oxygen saturation; PVR, pulmonary vascular resistance; RAP, right atrium pressure; WHO, World Health Organization.